166 related articles for article (PubMed ID: 32847723)
1. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
[TBL] [Abstract][Full Text] [Related]
2. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
[TBL] [Abstract][Full Text] [Related]
3. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
4. Considerations on activity assay discrepancies in factor VIII and factor IX products.
Ovanesov MV; Jackson JW; Golding B; Lee TK
J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
6. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
7. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
[TBL] [Abstract][Full Text] [Related]
8. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
9. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
Kitchen S; Kershaw G; Tiefenbacher S
Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
11. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
12. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
[TBL] [Abstract][Full Text] [Related]
13. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Kitchen S; Tiefenbacher S; Gosselin R
Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
[TBL] [Abstract][Full Text] [Related]
14. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
17. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
Abraham S; Duncan EM
Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
[TBL] [Abstract][Full Text] [Related]
18. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
Mikaelsson M; Oswaldsson U
Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
[TBL] [Abstract][Full Text] [Related]
19. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
[TBL] [Abstract][Full Text] [Related]
20. Activity measurements of dalcinonacog alfa.
Williams SC; Gray E
Haemophilia; 2020 Mar; 26(2):346-353. PubMed ID: 32142203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
